Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2020
Operating expenses:
Research and development		$ 11,057	$ 19,633
General and administrative	$ 31	3,984	5,002
Total operating expenses	31	15,041	24,635
Loss from operations	(31)	(15,041)	(24,635)
Other expense:
Change in fair value of preferred stock tranche liability			(17,030)
Interest expense		(1)	(28)
Total other expense		(1)	(17,058)
Net loss	$ (31)	$ (15,042)	$ (41,693)
Net loss per common share, basic and diluted	$ 0.00	$ (1.28)	$ (3.73)
Weighted average common shares outstanding, basic and diluted	8,715,999	11,733,170	11,176,429